102 completed, 4 terminated, 1 not yet recruiting, 1 recruiting. 57 Phase 1, 20 Phase 2, 19 Phase 3, 5 Phase 4.
By phase and status
Follow Astellas Pharma Europe B.V.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
Real-world Experiences and Voices Exploring the Actual Lived Burden of OAB: A Mixed-methods Multi-country PROMs Study on OAB Patients' Quality of Life
Overactive Bladder (OAB), Overactive Bladder Syndrome | | Not yet recruiting | European Association of Urology Research Foundation | 2000 | 2026-07-01 | 2026-05-06 |
Long-term Follow-up of the Offspring Born to Mothers With a Solid Organ Transplant, Transplantlines Next Generation
Solid Organ Transplantation, Pregnancy | | Recruiting | University Medical Center Groningen | 200 | 2025-10-15 | 2025-12-18 |
A Study of ASP8302 in Participants With Underactive Bladder
ASP8302, Placebo - Underactive Bladder | Phase 2 | Completed | Astellas Pharma Europe B.V. | 135 | 2018-11-20 | 2024-11-21 |
A Study of MA-0217 (ASP1128) in Healthy Adult Subjects and Healthy Elderly Subjects
ASP1128, Placebo - Healthy Volunteers | Phase 1 | Completed | Astellas Pharma Europe B.V. | 102 | 2017-11-20 | 2024-11-18 |
A Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects With Bladder Pain Syndrome/Interstitial Cystitis
ASP6294, Placebo - Bladder Pain Syndrome, Interstitial Cystitis | Phase 2 | Completed | Astellas Pharma Europe B.V. | 119 | 2017-09-28 | 2024-10-31 |
A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP7713 in Healthy Non-Japanese Adult and Elderly Subjects and Healthy Japanese Adult Subjects
ASP7713, Placebo - Healthy Volunteers | Phase 1 | Completed | Astellas Pharma Europe B.V. | 40 | 2017-05-23 | 2018-03-07 |
A Study To Assess The Efficacy And Safety Of Bismuth Tripotassium Dicitrate (De-Nol) In Combination With Pantoprazole And Pantoprazole Monotherapy In Treatment Of Subjects With Nonsteroidal Anti-Inflammatory Drugs (NSAID)-Induced Gastropathy
bismuth tripotassium dicitrate, pantoprazole - NSAID-induced Gastropathy | Phase 4 | Terminated | Astellas Pharma Europe B.V. | 9 | 2017-03-03 | 2017-09-21 |
A Phase 1 Study of Roxadustat in Subjects With Different Degrees of Renal Function
Roxadustat - Normal Renal Function, Impaired Renal Function | Phase 1 | Completed | Astellas Pharma Europe B.V. | 34 | 2016-12-12 | 2020-02-12 |
Open-label Phase 3 Study With Mirabegron in Children From 3 to Less Than 18 Years of Age With Neurogenic Detrusor Overactivity
Mirabegron - Neurogenic Detrusor Overactivity | Phase 3 | Completed | Astellas Pharma Europe B.V. | 91 | 2016-06-17 | 2024-11-12 |
A Study to Assess the Efficacy and Safety of Ipragliflozin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin
Ipragliflozin L-proline, Metformin, Placebo - Type 2 Diabetes Mellitus | Phase 3 | Completed | Astellas Pharma Europe B.V. | 268 | 2016-05-11 | 2024-11-12 |
A Study to Assess the Analgesic Efficacy of ASP7962 in Patients With Pain Due to Osteoarthritis of the Knee
ASP7962, Naproxen, Placebo - Osteoarthritis of the Knee, Chronic Lower Back Pain | Phase 2 | Completed | Astellas Pharma Europe B.V. | 215 | 2016-02-16 | 2024-10-31 |
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP6294 Administered Intravenously or Subcutaneously in Healthy Young Male and Female Subjects
ASP6294 Intravenous, ASP6294 Subcutaneous, Placebo Intravenous - Healthy Subjects, Pharmacokinetics of ASP6294 | Phase 1 | Completed | Astellas Pharma Europe B.V. | 74 | 2016-01-01 | 2017-01-10 |
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron Oral Suspension in Pediatric Subjects From 3 to Less Than 12 Years of Age With Neurogenic Detrusor Overactivity (NDO) or Overactive Bladder (OAB)
mirabegron - Overactive Bladder, Neurogenic Detrusor Overactivity | Phase 1 | Completed | Astellas Pharma Europe B.V. | 9 | 2015-12-17 | 2024-10-31 |
Personalizing Enzalutamide Therapy by Understanding the Relation Between Tumor mRNAs, miRNAs and Treatment Response
Enzalutamide, 160mg, 40 mg soft capsules, once daily - Metastatic Castration Resistant Prostate Cancer | | Completed | Radboud University Medical Center | 40 | 2015-10-01 | 2020-10-19 |
First-in-human: Single Ascending Dose, Food Effect, Drug-drug Interaction, Multiple Ascending Dose, Proof of Pharmacology
ASP6282, Itraconazole, Pilocarpine - Healthy Volunteers | Phase 1 | Completed | Astellas Pharma Europe B.V. | 116 | 2015-05-01 | 2016-07-01 |
A Study to Investigate the Effect of Oral Doses of Pilocarpine on Salivary Secretion and Static Pupillometry in Healthy Subjects
Pilocarpine, Placebo - Healthy Subjects | Phase 1 | Completed | Astellas Pharma Europe B.V. | 12 | 2015-05-01 | 2015-08-13 |
A Study to Evaluate ASP8232 as Add-On Therapy to Angiotensin Converting Enzyme Inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB) in Reducing Albuminuria in Patients With Type 2 Diabetes and Chronic Kidney Disease
ASP8232, Placebo - Chronic Kidney Disease, Type 2 Diabetes | Phase 2 | Completed | Astellas Pharma Europe B.V. | 125 | 2015-03-17 | 2024-10-31 |
Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis
Epoetin Alfa, Roxadustat - CKD Anemia in Stable Dialysis Patients | Phase 3 | Completed | Kyntra Bio | 741 | 2015-01-15 | 2021-10-29 |
A Study to Evaluate ASP8232 in Reducing Central Retinal Thickness in Subjects With Diabetic Macular Edema (DME)
ASP8232, ranibizumab, Placebo - Diabetes Mellitus, Diabetic Macular Edema | Phase 2 | Completed | Astellas Pharma Europe B.V. | 96 | 2015-01-12 | 2024-10-31 |
A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)
Fidaxomicin oral suspension, Fidaxomicin tablets, Vancomycin oral liquid - Clostridium Difficile-associated Diarrhea (CDAD) | Phase 3 | Completed | Astellas Pharma Europe B.V. | 148 | 2015-01-09 | 2024-11-26 |
Showing 20 of 110. Sign in to see all of them.
Conditions studied
Urinary Bladder, Overactive (13) · Renal Insufficiency, Chronic (8) · Urinary Incontinence (7) · Anemia (6) · Prostatic Neoplasms (5) · Diabetes Mellitus, Type 2 (4) · Kidney Failure, Chronic (4) · Diabetes Mellitus (3) · Lower Urinary Tract Symptoms (3) · Prostatic Hyperplasia (3) · Asthma (2) · Cystitis, Interstitial (2) · Kidney Diseases (2) · Nocturia (2) · Pain (2)
Interventions
Solifenacin Succinate (19) · mirabegron (14) · enzalutamide (12) · roxadustat (10) · ASP3652 (7) · Tamsulosin (6) · Itraconazole (5) · ipragliflozin (4) · opigolix (4) · ASP8232 (3) · Epoetin Alfa (3) · Leuprolide (3) · Tacrolimus (3) · ASP8477 (2) · Bendamustine Hydrochloride (2)
Countries
United Kingdom (46) · Germany (40) · Poland (32) · Belgium (28) · Netherlands (25) · Russia (24) · Czechia (23) · Spain (20) · France (19) · Hungary (18) · United States (16) · Denmark (15) · Italy (14) · Romania (14) · Ukraine (14)
Results publications
PMID 36005278, PMID 33231929, PMID 36749544, PMID 37160401, PMID 38363466, PMID 25917876, PMID 25929560, PMID 32007426, PMID 32715381, PMID 34362786, PMID 15466273, PMID 21878434, PMID 23424164, PMID 24136153, PMID 24612659, PMID 25209092, PMID 26227088, PMID 26947173, PMID 27182626, PMID 27687820, PMID 28218407, PMID 28844372, PMID 29866467, PMID 30413396, PMID 30598488, PMID 30674290, PMID 31067329, PMID 31356878, PMID 31388454, PMID 31606880, PMID 31773143, PMID 32239291, PMID 32408351, PMID 32734597, PMID 33165773, PMID 33657039, PMID 33732977, PMID 34058027, PMID 35419807, PMID 35992748, PMID 36942507, PMID 37811598, PMID 42481191
NIH funding
2014 (9), 2008 (7), 2009 (5), 2015 (4), 2004 (2), 2016 (2), 2017 (1)